Clinical trials: Precapillary Pulmonary Hypertension
High Altitude Pulmonary Hypertension
Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m
The interest of journeys to high altitude regions for recreational or professional purposes is increasing, also among potentially vulnerable groups including patients with chronic cardiopulmonary diseases such as pulmonary…
- Trial name
- NCT05107700
- Testing
- Stay at altitude 2500 m above sea level (high altitude), Stay at altitude 470 m above sea level (low altitude)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Hypertension, Precapillary Pulmonary Hypertension
Correlation Between CT Pulmonary Angiography Metrics and Right Heart Catheterization Parameters in Pre-Capillary Pulmonary Hypertension
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined by a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, as confirmed by right heart catheterization (RHC) (1).
- Conditions
- Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, CT Angiography
- Trial name
- NCT07667595
- Testing
- right heart catheter
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Pulmonary Hypertension
Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension
In this study, the investigators aim to describe the hemodynamic consequences of nasal high-flow measured during right heart catheterization and echocardiography.
- Trial name
- HighFlowHD (NCT06079151)
- Testing
- Nasal high-flow
- Where
- France
- Volunteers
- 20 people
- Sponsor
- ADIR Association
Pulmonary Hypertension, Precapillary Pulmonary Hypertension
Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
The goal of this observational study is to validate digital mobility outcomes for monitoring the treatment and disease progression in adult patients with pulmonary hypertension.
- Conditions
- Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, Digital Mobility Outcomes
- Trial name
- NCT07137260
- Testing
- Accelerometer (measurement of walking activity)
- Where
- 4 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Simon Jäger
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on ECG and Non-invasive Blood Pressure
Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on ECG repolarizations and non-invasive blood…
- Trial name
- NCT03581851
- Testing
- Simulated Altitude: (FiO2: 15.1)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep
The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on breathing and sleep of patients with pulmonary hypertension or with…
- Trial name
- NCT02150616
- Testing
- Moderate altitude sojourn, Low altitude sojourn, Oxygen
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Exposure to High Altitude on Exercise Capacity
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) in constant loaded exercise capacity.
- Trial name
- NCT03637153
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) on pulmonary artery pressure and right heart function (Echo) under exercise.
- Trial name
- NCT03637179
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Hypertension, Pulmonary
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH).
- Trial name
- HARMONIZE (NCT06814145)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Belgium and 10 more
- Volunteers
- 440 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Pulmonary Artery Pressure and Right Heart Function (Echo)
Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on pulmonary artery pressure and right heart…
- Trial name
- NCT03637088
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Sleep-Disordered Breathing, Pulmonary Arterial Hypertension
Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment
Evaluation of the effect of CPAP (continuous positive airway pressure ) treatment in PAH (pulmonary arterial hypertension) and CTEPH (chronic thromboembolic pulmonary hypertension) patients suffering from sleep disordered…
- Conditions
- Sleep-Disordered Breathing, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT02583906
- Testing
- CPAP
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Hypertension Associated With Connective Tissue Disease
VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of pulmonary hypertension it is approved for treatment.
- Trial name
- SIL-REACT (NCT01889966)
- Testing
- Sildenafil
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Kerckhoff Heart Center
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
High Altitude Pulmonary Hypertension, Oxygen Therapy
Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m
To study whether oxygen therapy titrated to maintain oxygenation (SpO2) > 90% at 2500m would resolve altitude-related adverse health effects, symptoms and impaired exercise during 30h exposure to high altitude.
- Trial name
- NCT05112172
- Testing
- Oxygen Therapy
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Exercise Endurance Time on the 2nd Day at 2500 m High Altitude
The impact of a sojourn at 2500 m of high altitude for 26-30 h on constant work-rate exercise test time in patients with precapillary pulmonary hypertension
- Trial name
- NCT05131737
- Testing
- High altitude exposure, Low altitude exposure
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
TEPH: Telaglenastat Efficacy in Pulmonary Hypertension
The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH).
- Trial name
- TEPH (NCT07223528)
- Testing
- Telaglenastat
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Chan, Stephen, MD, PhD
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Cognitive Function
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on cognitive functions.
- Trial name
- NCT03637127
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Precapillary Pulmonary Hypertension, Pulmonary Arterial Hypertension
Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension
Background and Rationale: Sleep-disordered breathing and nocturnal hypoxemia are highly prevalent in patients with precapillary pulmonary hypertension (PH), and current guidelines recommend systematic sleep assessment in this…
- Conditions
- Precapillary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Sleep-disordered Breathing, Nocturnal Hypoxemia
- Trial name
- HRV&PH (NCT07464184)
- Testing
- Standard Clinical and Functional Assessment, Overnight Polysomnography
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Rouen
Pulmonary Hypertension
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo)
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude ("Säntis"; 2500m above sea level) on pulmonary artery pressure and right heart function (echo)
- Trial name
- NCT03637166
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc